Literature DB >> 1168488

Kinetics in interactions between antibodies and haptens.

T W Smith, K M Skubitz.   

Abstract

Association and dissociation kinetics of antibody-hapten interactions of high affinity and specificity have been determined by newly developed techniques using dextran-coated charcoal for rapid separation of free and antibody-bound hapten. Interactions of 12 combinations of four antibody populations (rabbit digoxin-specific antibody, sheep digoxin-specific antibody, rabbit ouabain-specific antibody, and rabbit digitoxin-specific antibody) with three haptens ([3-H]digoxin, [3-H]ouabain, and [3-H]digitoxin) have been studied in terms of both association and dissociation kinetics, and compared in selected instances with association constants determined under equilibrium conditions. Association rate constants determined under both second-order and pseudo-first-order conditions were found to be similar for all antibody-hapten pairs studied (range 0.87-1.7 times 10-7 M-minus 1 sec- minus 1), and were comparable to values previously estimated for antibodies to dye haptens of markedly lower affinity. In contrast, dissociation rate constants varied markedly from 1.9 times 10- minus 4 to 1.7 times 10- minus 2 sec- minus 1. Ratios of association to dissociation rate constants measured by these methods were in satisfactory agreement with average intrinsic association constants measured under equilibrium conditions. These studies support the concept that the major kinetic variable governing antibody-hapten interactions is the rate of dissociation of the complex, and that the strength of antibody-hapten association is determined principally by the activation energy for dissociation.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1168488     DOI: 10.1021/bi00678a023

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  11 in total

Review 1.  The future of vaccines in the management of addictive disorders.

Authors:  Frank M Orson; Berma M Kinsey; Rana A K Singh; Yan Wu; Tracie Gardner; Thomas R Kosten
Journal:  Curr Psychiatry Rep       Date:  2007-10       Impact factor: 5.285

2.  Reversal of toxic and non-toxic effects of digoxin by digoxin-specific Fab fragments in isolated human ventricular myocardium.

Authors:  M Näbauer; E Erdmann
Journal:  Klin Wochenschr       Date:  1987-07-15

3.  Immunological probes in cardiovascular disease.

Authors:  K Jennings; P C Adams; I Gibb; A J Parnham
Journal:  Br Heart J       Date:  1982-12

4.  Reversal of advanced digitoxin toxicity and modification of pharmacokinetics by specific antibodies and Fab fragments.

Authors:  H R Ochs; T W Smith
Journal:  J Clin Invest       Date:  1977-12       Impact factor: 14.808

5.  Active immunotherapy for the Treatment of Cocaine Dependence.

Authors:  Berma M Kinsey; Thomas R Kosten; Frank M Orson
Journal:  Drugs Future       Date:  2010-04-01       Impact factor: 0.148

6.  Immunogenicity and kinetics of distribution and elimination of sheep digoxin-specific IgG and Fab fragments in the rabbit and baboon.

Authors:  T W Smith; B L Lloyd; N Spicer; E Haber
Journal:  Clin Exp Immunol       Date:  1979-06       Impact factor: 4.330

Review 7.  Substance abuse vaccines.

Authors:  Frank M Orson; Berma M Kinsey; Rana A K Singh; Yan Wu; Tracie Gardner; Thomas R Kosten
Journal:  Ann N Y Acad Sci       Date:  2008-10       Impact factor: 5.691

Review 8.  Vaccines for cocaine abuse.

Authors:  Frank M Orson; Berma M Kinsey; Rana A K Singh; Yan Wu; Thomas R Kosten
Journal:  Hum Vaccin       Date:  2009-04-20

9.  Beyond natural antibodies: the power of in vitro display technologies.

Authors:  Andrew R M Bradbury; Sachdev Sidhu; Stefan Dübel; John McCafferty
Journal:  Nat Biotechnol       Date:  2011-03       Impact factor: 54.908

10.  Human anti-self antibodies with high specificity from phage display libraries.

Authors:  A D Griffiths; M Malmqvist; J D Marks; J M Bye; M J Embleton; J McCafferty; M Baier; K P Holliger; B D Gorick; N C Hughes-Jones
Journal:  EMBO J       Date:  1993-02       Impact factor: 11.598

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.